Lung Cancer
From the Journals
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
A survey finds the COVID-19 pandemic to have a significant impact on oncologists’ decision-making.
From the Journals
NSCLC success story: Mortality down, survival improved
In recent years, mortality rates have fallen and survival has improved for patients with non–small cell lung cancer.
Conference Coverage
Sintilimab scintillates in first-line nonsquamous NSCLC
Conference Coverage
Chemo-free management of mesothelioma on horizon
News from the FDA/CDC
FDA approves first liquid biopsy/NGS test for lung cancer
Conference Coverage
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
The mortality rate was 8% among patients who received immune checkpoint inhibitors, which is comparable with the overall mortality rate among...
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
Feature
ASCO says ‘no’ to home infusions of cancer treatment, with exceptions
The American Society of Clinical Oncology has warned against intravenous infusion of chemotherapy and monoclonal antibodies in cancer patients’...
Conference Coverage
Higher death rate seen in cancer patients with nosocomial COVID-19
All-cause mortality was higher in cancer patients with hospital-acquired COVID-19 than in those with community-acquired COVID-19.
From the Journals
Experimental blood test detects cancer years before symptoms